Akari Therapeutics (AKTX) Webull Corporate Connect: Virtual Biotech Investment Webinar summary

Strategic vision and platform differentiation

• Focus on innovating antibody drug conjugates (ADCs) with novel immuno-oncology payloads designed to activate the immune system and target cancer cells more effectively than traditional cytotoxic ADCs.

• Lead payload, PH1, targets the spliceosome in cancer cells, causing cell death and making cancer cells appear foreign to the immune system, thus priming immune response.

• Lead asset AKTX-101 targets TROP2 and has shown robust preclinical activity, both as a single agent and in combination with checkpoint inhibitors.

• Early safety data from non-human primate studies indicate favorable dosing potential, supporting advancement to IND-enabling studies.

• Platform allows rapid development of multiple therapeutics by pairing PH1 with various antibodies for different cancer targets.

Market landscape and competitive positioning

• ADCs are a rapidly growing market, with recent multi-billion dollar acquisitions highlighting strong pharma interest.

• Most current ADCs use microtubule or TOPO1 inhibitors as payloads, while PH1 offers a novel mechanism by activating the immune system and overcoming resistance.

• PH1 payload is differentiated by its ability to synergize with checkpoint inhibitors and reduce off-target toxicity through advanced engineering.

• Preclinical data show PH1-based ADCs can induce immunological memory, potentially leading to durable remissions.

• Ongoing discussions with potential partners aim to leverage the unique platform for broader development and value creation.

Leadership, strategy, and future plans

• Recent leadership changes bring extensive oncology and ADC experience, with a focus on partnerships and business development.

• Strategic pivot from inflammation to oncology following acquisition of Peak Bio and its PH1 platform.

• Plans to outlicense legacy inflammation assets to fund oncology initiatives.

• Actively pursuing collaborations with big pharma and other partners to expand the platform's reach and create multiple value inflection points.

• Anticipates presenting new data later in the year and continuing to advance lead and pipeline assets toward clinical trials.